Curis Stock Price, News & Analysis

Curis, Inc. (CRIS) announced the launch of a Phase 2 trial called LUCAS to evaluate CA-4948, an IRAK4 kinase inhibitor, for anemia treatment in myelodysplastic syndromes (MDS) patients. The trial aims to enroll 84 patients, focusing on efficacy and safety, with recruitment starting in Q2 2021. Positive preliminary data from previous studies supports exploring CA-4948 for lower-risk MDS. The initiative involves collaboration with Dr. Uwe Platzbecker, enhancing Curis' clinical efforts in cancer therapeutics.

Curis, Inc. (NASDAQ: CRIS), a biotech firm specializing in cancer therapeutics, announced that CEO James Dentzer will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 21, 2021, at 11:00 am ET. A live webcast will be available on Curis's website, with a replay accessible for 90 days post-event. Curis collaborates with Aurigene on immuno-oncology and has ongoing trials for oncology treatments including CA-4948 and CI-8993.

On January 4, 2021, Curis (NASDAQ: CRIS) announced the grant of inducement stock options totaling 185,000 shares to three new employees. These options have an exercise price based on the company's closing stock price on the same day and a vesting period over four years. Each option vests 25% after the first year, followed by 6.25% every three months. This grant was made to incentivize new hires as part of the company's strategy to enhance its talent pool in the competitive biotechnology sector.

Curis, Inc. (NASDAQ: CRIS) has announced that CEO James Dentzer will present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference. The presentation will be available for on-demand viewing starting January 11, 2021, at 6:00 am ET. A live webcast can be accessed on the company's website under "Events & Presentations". Curis focuses on developing cancer therapeutics, with current collaborations on innovative treatments including CA-4948 and CI-8993, both in clinical trials. For more details, visit www.curis.com.

Curis, Inc. (NASDAQ: CRIS) has concluded its public offering of 29.5 million shares at $5.75 each, raising approximately $159.1 million in net proceeds. The offering included an option for underwriters to purchase an additional 3.8 million shares. Funds will be used to advance the development of cancer therapeutics CA-4948 and CI-8993, and to support general working capital until 2023. The offering was executed under a previously filed registration statement with the SEC.

Curis, Inc. (NASDAQ:CRIS) announced the pricing of a public offering of 25,652,174 shares at $5.75 per share, totaling approximately $147.5 million in gross proceeds. The offering is expected to close around December 11, 2020, pending customary conditions. Proceeds will be used for the development of CA-4948 and CI-8893, along with general working capital. The offering is made under a shelf registration statement and involves underwriters such as Cantor Fitzgerald & Co. and JonesTrading Institutional Services.

Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, has announced a proposed public offering of its common stock under an existing shelf registration statement. The company plans to grant underwriters a 30-day option to purchase additional shares, up to 15% of the offering size. Proceeds will fund the development of CA-4948 and CI-8993, while also supporting general working capital. Cantor Fitzgerald & Co. and JonesTrading are the joint lead book runners for this offering.

Curis (NASDAQ: CRIS) announced promising preliminary results from its Phase 1 study of CA-4948, an IRAK4 kinase inhibitor targeting acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Key findings include marrow blast reductions in all evaluable patients, with no dose-limiting toxicities reported. Out of 7 patients, 6 remain in the study. The results highlight CA-4948's potential, especially for patients who are relapsed or refractory. The company plans to provide further updates on the study in mid-2021.

Curis (NASDAQ: CRIS) announced updated data from its Phase 1 study of CA-4948, an IRAK4 kinase inhibitor for relapsed or refractory non-Hodgkin's lymphoma (NHL). Results indicate that the recommended Phase 2 dose of 300 mg BID demonstrates significant anti-cancer activity with a median tumor reduction of 27% in evaluable patients. The drug is well-tolerated, and preliminary data from biomarkers suggest potential for patient enrichment. A virtual presentation of these findings will occur at the 62nd American Society of Hematology Annual Meeting.